Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FBXW7 S462P |
| Therapy | JQ1 + Ulixertinib |
| Indication/Tumor Type | adult T-cell leukemia/lymphoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FBXW7 S462P | adult T-cell leukemia/lymphoma | sensitive | JQ1 + Ulixertinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination treatment of JQ1 and Ulixertinib (BVD-523) resulted in greater decreased proliferation of adult T cell leukemia cells expressing FBXW7 S462P when compared to treatment with JQ1 alone in culture (PMID: 32907612). | 32907612 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (32907612) | Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells. | Full reference... |